Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: STEM stock price vs GILD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GILD's multiple
Needs Annual EPS, GILD P/E.
Implied fair value · at STEM's multiple
Needs Annual EPS, STEM P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
STEM, INC. · implied price per share
Reporting currency could not be verified.
GILEAD SCIENCES, INC. · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
STEM · not enough data.
GILD · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Enphase Energy, Inc.
STEM vs ENPH
Fluence Energy, Inc.
STEM vs FLNC
Tesla, Inc.
STEM vs TSLA
ITRON, INC.
STEM vs ITRI
AbbVie Inc.
STEM vs ABBV
AMGEN INC
STEM vs AMGN
BRISTOL MYERS SQUIBB CO
STEM vs BMY
Merck & Co., Inc.
STEM vs MRK
PFIZER INC
STEM vs PFE
REGENERON PHARMACEUTICALS, INC.
STEM vs REGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe STEM can sustain its revenue growth while materially improving operating margins and avoiding distress, then the stock could merit a speculative long because it trades far below both GILD-implied and DCF valuation ranges; otherwise, the weak Altman Z-Score argues against assuming the discount is purely an opportunity.
On a relative basis, STEM trades at a steep discount to GILD across both P/S and EV-based measures, while the modeled implied price suggests very large upside versus the current quote. However, the market appears to be pricing STEM off a much weaker fundamentals and quality profile than GILD, which helps explain the disconnect.
Supporting Metrics
